Radiotherapy for Thoracic Malignancies: New Advances and Challenges (Volume II)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 114
Special Issue Editor
Interests: radiotherapy; stereotactic body radiation therapy; non-small cell lung cancer; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are excited to invite you to contribute to this Special Issue, which is the second edition of "Radiotherapy for Thoracic Malignancies: New Advances and Challenges" (https://www.mdpi.com/journal/cancers/special_issues/R_LC).
As the Guest Editor for this Special Issue of the journal Cancers, I would like to reach out to request your contribution as an expert in the field of thoracic radiation oncology.
Recent advances in thoracic oncology have significantly improved our understanding of lung cancer and other thoracic malignancies, offering critical insight into the selection of therapeutic approaches. The gains in the field have been multifaceted and complementary. Refinements in diagnostic imaging have improved our ability to detect cancers and accurately stage patients. Routine molecular characterization of lung cancers has led to the identification and validation of prognostic and predictive biomarkers. The widespread adoption of immunotherapy for advanced and metastatic lung cancer, as well as promising findings in small cohorts of earlier-stage disease, has offered an additional therapeutic approach with impressive clinical outcomes in a subset of patients. In this setting and concomitant with all these advances, there has been a broad adoption of advanced image guidance technologies and stereotactic body radiation therapy, which are central to the recent therapeutic gains by radiotherapy in lung cancer.
In this Special Issue, we will highlight key recent advances in radiotherapy for lung cancer and other thoracic malignancies. We will focus on current clinical evidence, summarize pertinent trials, and identify ongoing challenges. In line with the increasing appreciation of the heterogeneity of malignancies, we will discuss emerging concepts on personalized therapy for lung cancer.
Dr. Eric C. Ko
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiotherapy
- stereotactic body radiation therapy
- non-small cell lung cancer
- immunotherapy
- thoracic oncology
